Company Overview

Vivos Inc. is a clinical-stage biotechnology company focused on the development of localized radiotherapy treatments for cancer. The company operates within the biopharmaceutical and medical oncology industries, with its core emphasis on solid tumor treatment using injectable radiopharmaceutical technologies. Vivos Inc.’s primary product candidate is RadioGel™ Precision Oncology, an investigational injectable hydrogel that delivers beta-emitting radioisotopes directly into tumors, with the intent of minimizing damage to surrounding healthy tissue.

The company’s business model is centered on advancing RadioGel™ Precision Oncology through clinical development and regulatory pathways, with potential future commercialization through direct sales, licensing, or strategic partnerships. Vivos Inc. primarily targets oncology providers treating solid tumors, including veterinary and human cancer markets. The company positions itself as a provider of localized, minimally invasive cancer treatment with potential advantages in precision, safety, and cost compared to traditional external beam radiation therapy. Vivos Inc. traces its origins to technology development efforts in radiopharmaceutical delivery systems and later became publicly traded on the OTC Markets under the ticker RDGL as it focused its operations on oncology applications.

Business Operations

Vivos Inc.’s operations are primarily organized around the research, development, and regulatory advancement of RadioGel™ Precision Oncology. The company does not currently report commercial product revenue and instead focuses on preclinical studies, veterinary clinical use, and preparation for human clinical trials. Its revenue, where applicable, has historically been derived from limited veterinary applications and research-related activities rather than broad commercial sales.

The company conducts its operations mainly within the United States and relies on a combination of internal research capabilities and third-party service providers for manufacturing, testing, and regulatory support. Vivos Inc. operates through its wholly owned subsidiary Vivos Medical, Inc., which holds key intellectual property related to the RadioGel technology. Public disclosures indicate no large-scale joint ventures or revenue-generating strategic partnerships as of the most recent reporting periods; data inconclusive based on available public sources regarding long-term commercial agreements.

Strategic Position & Investments

Strategically, Vivos Inc. is focused on advancing RadioGel™ Precision Oncology through regulatory milestones, including expanded veterinary use and eventual human clinical trials under U.S. regulatory oversight. The company’s growth strategy emphasizes proof-of-concept validation, safety data generation, and intellectual property protection as prerequisites for broader commercialization or licensing opportunities.

Vivos Inc. has made targeted investments in research infrastructure, regulatory consulting, and manufacturing readiness to support future clinical trials. The company’s disclosed investment activity centers on internal development rather than acquisitions, and no material acquisitions have been consistently verified across public filings. Its strategic positioning reflects a long-term approach aimed at entering emerging localized radiotherapy markets, though commercialization timelines remain subject to regulatory outcomes and funding availability.

Geographic Footprint

Vivos Inc. is headquartered in the United States, with its principal executive offices and research oversight based domestically. Its operational footprint is largely U.S.-centric, reflecting its focus on compliance with U.S. regulatory frameworks and clinical development pathways.

Internationally, the company’s presence is limited and primarily indirect, consisting of intellectual property considerations and potential future market opportunities rather than established overseas operations. There is no verified evidence of significant foreign subsidiaries or manufacturing facilities outside the United States as of the latest public disclosures; data inconclusive based on available public sources regarding sustained international operations.

Leadership & Governance

Vivos Inc. is led by a management team with experience in biotechnology, pharmaceuticals, and medical innovation. The company’s leadership emphasizes scientific rigor, regulatory compliance, and the long-term development of oncology-focused technologies.

Key executives include:

• Scott Quay, MD, PhD – Chief Executive Officer
• Scott Quay, MD, PhD – Chairman of the Board
• Additional executive officer disclosures – Data inconclusive based on available public sources regarding consistently reported titles and roles beyond the CEO and Chairman positions across recent filings

The leadership’s stated strategic vision centers on advancing localized cancer therapies that improve treatment precision while reducing systemic toxicity, with governance structured around board oversight and compliance with U.S. public company reporting requirements.